The Food and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the first blood-based test that ...

The test can aid doctors in determining whether a patient’s memory problems are due to Alzheimer’s or a number of other ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with ...

While similar to lecanemab (Leqembi), an earlier FDA-approved infusion, donanemab introduces new possibilities in how Alzheimer’s can be managed—and potentially paused. Donanemab is a ...

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with ...